Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Osteoarthritis 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Brain Stem Neoplasms 1Brain Neoplasms 1Barrett Esophagus 1Advanced Non-small Cell Lung Cancer 1Adenomatous Polyposis Coli 1

Interventions

rofecoxib 1acetaminophen, codeine drug combination 1World Health Organization oral rehydration solution 1Vitamin D 1Syringes 1Oxycodone 1Nutrition Assessment 1Naloxone 1Inosine Monophosphate 1Fish Oils 1Fatty Acids, Omega-3 1Eicosapentaenoic Acid 1Duration of Therapy 1Docosahexaenoic Acids 1Cholecalciferol 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Osteoarthritis × rofecoxib × Clear all
NCT00140894 2019-09-20

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
62 enrolled
Gastrointestinal

Cancer Pain, Osteoarthritis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡